Allergan Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?
ALLERGAN has seventy-three approved drugs.
There are nine US patents protecting ALLERGAN drugs.
There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and sixteen supplementary protection certificates in eighteen countries.
Summary for Allergan
International Patents: | 181 |
US Patents: | 9 |
Tradenames: | 70 |
Ingredients: | 54 |
NDAs: | 73 |
Patent Litigation for Allergan: | See patent lawsuits for Allergan |
PTAB Cases with Allergan as patent owner: | See PTAB cases with Allergan as patent owner |
Drugs and US Patents for Allergan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan Herbert | PENECORT | hydrocortisone | GEL;TOPICAL | 088215-001 | Jun 6, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Allergan | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-006 | Oct 27, 2006 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Allergan | ACULAR PRESERVATIVE FREE | ketorolac tromethamine | SOLUTION/DROPS;OPHTHALMIC | 020811-001 | Nov 3, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-001 | Aug 13, 2009 | AB | RX | Yes | No | 8,022,228*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-003 | Mar 12, 2015 | AB | RX | Yes | No | 7,741,358*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-002 | Aug 13, 2009 | AB | RX | Yes | Yes | 8,022,228*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Allergan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-001 | Jun 13, 1997 | 5,914,334 | ⤷ Try a Trial |
Allergan | BYSTOLIC | nebivolol hydrochloride | TABLET;ORAL | 021742-005 | Oct 8, 2008 | 6,545,040 | ⤷ Try a Trial |
Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-002 | May 29, 1992 | 4,839,177 | ⤷ Try a Trial |
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | 8,241,662 | ⤷ Try a Trial |
Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-002 | May 29, 1992 | 5,422,123 | ⤷ Try a Trial |
Allergan | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-006 | Oct 27, 2006 | 5,378,474 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 4 mg and 8 mg | ➤ Subscribe | 2012-10-09 |
➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-08-13 |
➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
➤ Subscribe | Ophthalmic Solution | 0.30% | ➤ Subscribe | 2007-07-19 |
➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
➤ Subscribe | Sublingual Tablets | 2.5 mg | ➤ Subscribe | 2017-07-27 |
International Patents for Allergan Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Morocco | 26351 | ⤷ Try a Trial |
Slovenia | 1480644 | ⤷ Try a Trial |
Serbia | 50214 | ⤷ Try a Trial |
Russian Federation | 2610091 | ⤷ Try a Trial |
Hungary | S1600055 | ⤷ Try a Trial |
Poland | 3269717 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Allergan Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0392059 | 2002C/035 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517 |
1534313 | 15C0090 | France | ⤷ Try a Trial | PRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728 |
1480644 | 629 | Finland | ⤷ Try a Trial | |
1480644 | 58/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AUS CEFTAZIDIM UND AVIBACTAM; REGISTRATION NO/DATE: EU/1/16/1109 (MITTEILUNG) 20160628 |
2782584 | 301153 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406 |
1480644 | 1690059-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PHARMACEUTICAL MIXTURE OR ASSOCIATION THAT INCLUDES AS ACTIVE INGREDIENTS: (1) CEFTAZIDIME OR A SALT THEREOF, AND (2) AVIBACTAM OR A SALT THEREOF; REG. NO/DATE: EU/1/16/1109 20160628 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.